Booster dose after 10 years is recommended following 17DD-YF primary vaccination

References

• Monath TP. Yellow fever: an update. Lancet Infect Dis 2001; 1:11-20; PMID:11871403; http://dx.doi.org/10.1016/S1473-3099(01)00016-0
   PubMedGoogle Scholar
• Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981; 59: 895-900; PMID:6978196
   PubMed Web of Science ®Google Scholar
• Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, Quyyumi F, Garg S, Altman JD, Del Rio C, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 2009; 183:7919-30; PMID:19933869; http://dx.doi.org/10.4049/jimmunol.0803903
   PubMed Web of Science ®Google Scholar
• Collaborative group for studies on yellow fever vaccines. Duration of post-vaccination immunity against yellow fever in adults. Vaccine 2014; 32:4977-84; PMID:25090646; http://dx.doi.org/10.1016/j.vaccine.2014.07.021
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 2013; 89:434-44; PMID:24006295; http://dx.doi.org/10.4269/ajtmh.13-0264
   PubMed Web of Science ®Google Scholar
• Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, Moser JM, Mehta RS, Drake DR, Castro E, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008; 205:3119-31; PMID:19047440; http://dx.doi.org/10.1084/jem.20082292
   PubMed Web of Science ®Google Scholar
• Bassi MR, Kongsgaard M, Steffensen MA, Fenger C, Rasmussen M, Skjødt K, Finsen B, Stryhn A, Buus S, Christensen JP, Thomsen AR. CD8+ T cells complement antibodies in protecting against yellow fever virus. J Immunol 2015; 194: 1141-53; PMID:25539816; http://dx.doi.org/10.4049/jimmunol.1402605
   PubMed Web of Science ®Google Scholar
• Querec TD, Rama SA, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2008; 10:116-25; PMID:19029902; http://dx.doi.org/10.1038/ni.1688
   PubMed Web of Science ®Google Scholar
• Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, Shope RE, Thomas N, Schrader R, Furby D, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002; 66: 533-41; PMID:12201587
   PubMed Web of Science ®Google Scholar
• Muyanja E, Ssemaganda A, Ngauv P, Cubas R, Perrin H, Srinivasan D, Canderan G, Lawson B, Kopycinski J, Graham AS, et al. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest 2014; 124:3147-58
   PubMed Web of Science ®Google Scholar
• (WHO) 2008. WHO: Expert Committee on Biological Standardization: Requirements for yellow fever vaccine. In Bolletin Requirements for Biological Substances. Geneve: WHO.
   Google Scholar
• Campi-Azevedo AC, de Araújo-Porto LP, Luiza-Silva M, Batista MA, Martins MA, Sathler-Avelar R, da Silveira-Lemos D, Camacho LA, de Menezes M R, de Lourdes de S. et al. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children. PLoS One 2012; 7(12):e49828; PMID:23251351; http://dx.doi.org/10.1371/journal.pone.0049828
   PubMed Web of Science ®Google Scholar
• Martins MA, Silva ML, Marciano AP, Peruhype-Magalhães V, Eloi-Santos SM, Ribeiro JG, Correa-Oliveira R, Homma A, Kroon EG, Teixeira-Carvalho A, et al. Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization? Clin Exp Immunol 2007; 148:90-100; PMID:17309541; http://dx.doi.org/10.1111/j.1365-2249.2006.03317.x
   PubMed Web of Science ®Google Scholar
• Ravindran R, Khan N, Nakaya HI, Li S, Loebbermann J, Maddur MS, Park Y, Jones DP, Chappert P, Davoust J, et al. Vaccine activation of the nutrient sensor GCN2 in dendritic cells enhances antigen presentation. Science 2014; 343:313-7; PMID:24310610; http://dx.doi.org/10.1126/science.1246829
   PubMed Web of Science ®Google Scholar
• Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN, Heath WR, Carbone FR, Gebhardt T. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci USA 2012; 109:7037-42; PMID:22509047; http://dx.doi.org/10.1073/pnas.1202288109
   PubMed Web of Science ®Google Scholar
• Tan WG, Jin HT, West EE, Penaloza-MacMaster P, Wieland A, Zilliox MJ, McElrath MJ, Barouch DH, Ahmed R. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J Virol 2013; 87:1359-72; PMID:23175355; http://dx.doi.org/10.1128/JVI.02055-12
   PubMed Web of Science ®Google Scholar
• Virnik K, Hockenbury M, Ni Y, Beren J, Pavlakis GN, Felber BK, Berkower I. Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques. Retrovirology 2013; 10-99; PMID:23369348
   PubMed Web of Science ®Google Scholar
• Hatch GJ, Graham VA, Bewley KR, Tree JA, Dennis M, Taylor I, Funnell SG, Bate SR, Steeds K, Tipton T, Bean T, Hudson L, Atkinson DJ, McLuckie G, Charlwood M, Roberts AD, Vipond J. Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. J Virol 2013; 87:7805-15; PMID:23658452; http://dx.doi.org/10.1128/JVI.03481-12
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Zephir K, Hu Z, Wei CJ, Chang L, Enama ME, Hendel CS, Sitar S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Graham BS. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 2013; 208:418-22; PMID:23633407; http://dx.doi.org/10.1093/infdis/jit180
   PubMed Web of Science ®Google Scholar
• Khurana S, Wu J, Dimitrova M, King LR, Manischewitz J, Graham BS, Ledgerwood JE, Golding H. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J Infect Dis 2013; 208:413-7; PMID:23633404; http://dx.doi.org/10.1093/infdis/jit178
   PubMed Web of Science ®Google Scholar
• Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci USA 2012; 109:5797-802; PMID:22454499; http://dx.doi.org/10.1073/pnas.1117208109
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Murphy KE, Kunkel EJ, Brightling CE, Soler D, Shen Z, Boisvert J, Greenberg HB, Vierra MA, Goodman SB, et al. CCR7 expression and memory T cell diversity in humans. J. Immunol 2001; 166:877-84; PMID:11145663; http://dx.doi.org/10.4049/jimmunol.166.2.877
   PubMed Web of Science ®Google Scholar
• Simões M, Camacho LAB, Yamamura AMY, Miranda EH, Cajaraville ACRA, Freire MS. Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies. Biologicals 2012; 40:399-404; PMID:23034357; http://dx.doi.org/10.1016/j.biologicals.2012.09.005
   PubMed Web of Science ®Google Scholar
• Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998; 56: 159-67; PMID:9746073; http://dx.doi.org/10.1002/(SICI)1096-9071(199810)56:2%3c159::AID-JMV10%3e3.0.CO;2-B
   PubMed Web of Science ®Google Scholar
• Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008; 28:710-22; PMID:18468462; http://dx.doi.org/10.1016/j.immuni.2008.02.020
   PubMed Web of Science ®Google Scholar
• Campi-Azevedo AC, Estevam P de A, Coelho-dos-Reis JG, Peruhype-Magalhães V, Villela-Rezende G, Quaresma PF, Maia M de L S, Farias RHG, Camacho LAB, Freire M da S, et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect Dis 2014; 15:14-391
   Google Scholar
• Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. Nat Rev Immunol 2013; 13:875-87; PMID:24157572; http://dx.doi.org/10.1038/nri3547
   PubMed Web of Science ®Google Scholar
• Peruhype-Magalhães V, Martins-Filho OA, Prata A, Silva L de A, Rabello A, Teixeira-Carvalho A, Figueiredo RM, Guimarães-Carvalho SF, Ferrari TC, Van Weyenbergh J, et al. Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection. Clin Exp Immunol 2006; 146: 124-32; PMID:16968407; http://dx.doi.org/10.1111/j.1365-2249.2006.03171.x
   PubMed Web of Science ®Google Scholar
• Silva ML, Martins MA, Espírito-Santo LR, Campi-Azevedo AC, Silveira-Lemos D, Ribeiro JG, Homma A, Kroon EG, Teixeira-Carvalho A, Elói-Santos SM, et al. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine 2011; 29:583-92; PMID:20732465; http://dx.doi.org/10.1016/j.vaccine.2010.08.046
   PubMed Web of Science ®Google Scholar